By Fineline Cube Adlai Nortye (NASDAQ: ANL) announced that the company’s independently developed antibody-drug conjugate (ADC) AN4035, which targets CEACAM5 and carries a pan-RAS(ON) inhibitor payload, has been submitted as a Clinical Trial Notification (CTN) to the Australian Therapeutic Goods Administration (TGA) and has received approval from the Human Research Ethics Committee (HREC).
Regulatory Milestone
| Item | Detail |
|---|---|
| Company | Adlai Nortye (NASDAQ: ANL) |
| Product | AN4035 |
| Regulatory Status | TGA CTN approval and HREC ethical clearance |
| Indication | CEACAM5-high expressing and RAS-dependent solid tumors |
| Trial Phase | Phase 1 |
| Announcement Date | 3 Aug 2026 |
Drug Profile & Innovation
- Molecule Type: First-in-class CEACAM5-targeting antibody-drug conjugate (ADC)
- Payload: Highly potent pan-RAS(ON) inhibitor
- Significance: World’s first pan-RAS(ON) antibody-drug conjugate to enter clinical development
- Mechanism: Precisely targets tumor sites while minimizing systemic inhibition of the RAS pathway
- Target Population: Patients with CEACAM5-high expressing, RAS-dependent solid tumors
Clinical Development Plan
The global Phase 1 clinical trial in Australia will evaluate:
- Safety and tolerability
- Pharmacokinetics and pharmacodynamics
- Preliminary anti-tumor efficacy
The study will assess AN4035 both as a monotherapy and in combination with cetuximab in patients with CEACAM5-high expressing, RAS-dependent solid tumors.
Strategic Significance
RAS mutations occur in approximately 30% of all human cancers, making them one of the most common oncogenic drivers. However, direct targeting of RAS proteins has historically been challenging due to their structure and function. AN4035’s innovative approach of delivering a pan-RAS(ON) inhibitor specifically to tumor cells via CEACAM5 targeting represents a breakthrough strategy that could overcome the limitations of systemic RAS inhibition.
CEACAM5 is overexpressed in various solid tumors including colorectal, gastric, pancreatic, and lung cancers, providing a broad potential addressable patient population.
Market Opportunity & Competitive Landscape
- Global ADC Market: Projected to exceed $20 billion by 2030
- RAS-Targeted Therapies: Significant unmet medical need with limited approved options
- Competitive Positioning: First-in-class mechanism with dual targeting approach (CEACAM5 + pan-RAS(ON))
- Commercial Potential: Global rights retained by Adlai Nortye with potential for strategic partnerships post proof-of-concept
Company Pipeline Strategy
“This dual approval from Australian regulatory authorities validates our scientific approach and accelerates our clinical development timeline,” said Dr. Li Xiangdong, Chief Scientific Officer at Adlai Nortye. “AN4035 embodies our commitment to developing innovative cancer therapeutics through our proprietary ADC platform, and we’re excited to advance this promising candidate into human clinical trials.”
The company expects to initiate patient enrollment immediately, with initial safety data anticipated within 12-18 months. The Phase I trial will employ a dose-escalation design to determine the maximum tolerated dose and recommended Phase II dose.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial expectations. Actual results may differ due to clinical trial outcomes, regulatory decisions, competitive dynamics, and market adoption.-Fineline Info & Tech